{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:55:23Z","timestamp":1789084523696,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.cgh.2017.12.009","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T19:03:53Z","timestamp":1513105433000},"page":"765-773.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-2464","authenticated-orcid":false,"given":"Terry","family":"Cheuk-Fung Yip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Wai-Sun Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Lik-Yuen Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Kit","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Pik-Shan Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Long-Yan Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chung-Yan Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-9389","authenticated-orcid":false,"given":"Grace","family":"Lai-Hung Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2017.12.009_bib1","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2017.12.009_bib2","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after\u00a0nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.12.009_bib3","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1053\/gast.2002.36026","article-title":"Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection","volume":"123","author":"Chen","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.12.009_bib4","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jhep.2017.06.019","article-title":"Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance","volume":"67","author":"Yip","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2017.12.009_bib5","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(14)60886-2","article-title":"The global implications of diabetes and cancer","volume":"383","author":"Shi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2017.12.009_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.semcancer.2013.07.003","article-title":"Obesity, insulin resistance, NASH and hepatocellular carcinoma","volume":"23","author":"Yu","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.cgh.2017.12.009_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1741-7015-12-76","article-title":"Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes","volume":"12","author":"Kong","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.cgh.2017.12.009_bib8","first-page":"985","article-title":"Erratum. Glycemic targets. Sec. 6. In Standards of Medical Care in Diabetes-2017. Diabetes Care 2017;40:S48\u2013S56","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cgh.2017.12.009_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/ERC-12-0290","article-title":"Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes","volume":"20","author":"Yang","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.cgh.2017.12.009_bib10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.14172","article-title":"Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population","volume":"46","author":"Yip","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.12.009_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2017.12.009_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2017.12.009_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.12.009_bib14","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2017.12.009_bib15","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/jhep.2002.36780","article-title":"Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus","volume":"36","author":"Hassan","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.12.009_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2008.03.073","article-title":"Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B\/C infection: a follow-up study in Taiwan","volume":"135","author":"Chen","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.12.009_bib17","doi-asserted-by":"crossref","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cgh.2017.12.009_bib18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression\u00a0of\u00a0non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years","volume":"59","author":"Wong","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.12.009_bib19","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and\u00a0risk\u00a0factors of hepatocellular carcinoma in patients with\u00a0nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.12.009_bib20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","article-title":"Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma","volume":"126","author":"El-Serag","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.12.009_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cgh.2013.07.040","article-title":"Insulin resistance, obesity, and liver cancer","volume":"12","author":"Farrell","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.12.009_bib22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jhep.2011.09.020","article-title":"Obesity, inflammation, and liver cancer","volume":"56","author":"Sun","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2017.12.009_bib23","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.12.009_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2017.12.009_bib25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2017.12.009_bib26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/apt.14341","article-title":"Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis","volume":"46","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.12.009_bib27","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","article-title":"Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma","volume":"53","author":"Chan","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.12.009_bib28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/apt.12207","article-title":"Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma","volume":"37","author":"Wong","year":"2013","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517314507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517314507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:24:26Z","timestamp":1761542666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356517314507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1542356517314507"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2017.12.009","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2017.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the AGA Institute","name":"copyright","label":"Copyright"}]}}